Back to Journals » OncoTargets and Therapy » Volume 11

Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis

Authors Sun TT, Tang YR, Sun DW, Bu Q, Li P

Received 3 September 2018

Accepted for publication 2 November 2018

Published 10 December 2018 Volume 2018:11 Pages 8925—8935

DOI https://doi.org/10.2147/OTT.S186230

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Dr Federico Perche


Tingting Sun,1,* Yurong Tang,1,* Diwen Sun,2 Qingao Bu,2 Peng Li2

1Department of Clinical Laboratory, Shengli Oilfield Central Hospital, Dongying 257000, Shandong, China; 2Department of Breast and Thyroid Surgery, Shengli Oilfield Central Hospital, Dongying 257000, Shandong, China

*These authors contributed equally to this work

Background: Several studies have reported that osteopontin (OPN) is a promising marker for the diagnosis of hepatocellular carcinoma (HCC); however, some studies emerged with conflicting results. Therefore, we provide a systematic review to evaluate the diagnostic performance of OPN for HCC.
Methods: Studies that investigated the diagnostic value of OPN and alpha-fetoprotein (AFP) in HCC were collected from PubMed and Embase. Sensitivity, specificity, and other parameters about the diagnostic accuracy of serum OPN and AFP in HCC were pooled using STATA 12.0 software. The summary receiver operating characteristic curve (sROC) and other parameters were used to summarize the overall test performance.
Results: Twelve studies were included in our meta-analysis. Pooled sensitivity, specificity, and diagnostic odds ratio were 0.813 (95% CI: 0.671–0.902), 0.874 (95% CI: 0.778–0.932), and 30.047 (95% CI: 8.845–102.067) for OPN; 0.639 (95% CI: 0.538–0.729), 0.959 (95% CI: 0.909–0.982), and 41.518 (95% CI: 13.688–125.929) for AFP; and 0.856 (95% CI: 0.760–0.918), 0.738 (95% CI: 0.630–0.823), and 16.718 (95% CI: 7.950–35.156) for OPN+AFP, respectively. The area under the sROC for OPN, AFP, and OPN+AFP was 0.91, 0.88, and 0.85, respectively. For diagnosis of early HCC, pooled sensitivity of serum OPN, AFP, and OPN+AFP was 0.493 (95% CI: 0.422–0.563), 0.517 (95% CI: 0.446–0.587), and 0.732 (95% CI: 0.666–0.791), respectively.
Conclusions: OPN is a comparable marker to AFP for the diagnosis of HCC, and the sensitivity of OPN was higher than that of AFP. A combination of AFP and OPN can elevate the sensitivity of diagnosis for early HCC.

Keywords: OPN, AFP, HCC, diagnosis, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]